Onpattro is a medication that has been approved by the FDA for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). This rare genetic disorder can lead to the accumulation of abnormal amyloid proteins in various tissues, including the nerves, which can result in nerve damage and symptoms such as numbness, tingling, and weakness in the extremities.

Onpattro works by targeting the production of the abnormal transthyretin protein, which is responsible for the formation of amyloid deposits. By reducing the levels of this protein, Onpattro can help slow down the progression of the disease and improve symptoms in patients with hATTR polyneuropathy.

It is important to follow the dosing schedule prescribed by your healthcare provider and to report any side effects or concerns while taking Onpattro. Common side effects may include infusion-related reactions, so it is important to receive this medication in a healthcare setting where you can be monitored for any potential reactions.

As a medical professional, I recommend discussing the potential benefits and risks of Onpattro with your healthcare provider to determine if this medication is right for you. It is important to continue regular follow-up appointments and monitoring while taking Onpattro to ensure that you are receiving the best possible care for your condition.

Overall, Onpattro represents a significant advancement in the treatment of hATTR polyneuropathy and offers hope for patients living with this rare and debilitating disease. If you have any questions or concerns about Onpattro, do not hesitate to reach out to your healthcare provider for more information.